A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd). The ...
AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...
With 15 football state championships between the two teams, the Class 4A quarterfinals should be well-attended. On Saturday, 10th-seeded Sacred Heart-Griffin forced four turnovers, quarterback Cam ...
What’s the latest news regarding the war in Ukraine? When are the next French elections? What activites can I do with children while visiting Paris? Your questions answered, based on articles, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback